Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Response Evaluation Criteria in Solid Tumors Can be Substituted for the International Workshop Criteria?: Comparison Using Japan Clinical Oncology Group Study JCOG0203 for Untreated Indolent B-Cell Lymphoma

Kenichi Miyamoto, MD, Takashi Watanabe, MD PhD, Hideaki Kitahara, MD, Masashi Wakabayashi, MSc, Kenichi Nakamura, MD, Yuko Watanabe, Dai Maruyama, MD PhD, Kensei Tobinai, MD, PhD, Kunihiro Tsukasaki, MD, Haruhiko Fukuda, MD

Blood (2016) 128 (22): 4779.

https://doi.org/10.1182/blood.V128.22.4779.4779

Published: 2016

Journal Articles

Prolonged Lymphocytepenia after Bendamustine with or without Rituximab Treatment in Patients with Relapsed or Refractory Indolent B-Cell and Mantle Cell Lymphoma

Hideaki Saito, MD, Dai Maruyama, MD PhD, Akiko Miyagi Maeshima, MD PhD, Shin-ichi Makita, MD, Hideaki Kitahara, MD, Ken-ichi Miyamoto, MD, Suguru Fukuhara, MD, Wataru Munakata, MD, Tatsuya Suzuki, MD PhD, Yukio Kobayashi, Hirokazu Taniguchi, MD PhD, Kensei Tobinai

Blood (2014) 124 (21): 3066.

https://doi.org/10.1182/blood.V124.21.3066.3066

Published: 2014

Journal Articles

The Impact of Concurrent Expression of MYC and BCL2 on Outcomes of Localized Primary Gastric Diffuse Large B-Cell Lymphoma Undergoing Rituximab-Containing Chemotherapy with or without Radiotherapy

Akihisa Kawajiri, MD, Dai Maruyama, MD PhD, Akiko Miyagi Maeshima, MD PhD, Shin-ichi Makita, MD, Hideaki Kitahara, MD, Ken-ichi Miyamoto, MD, Suguru Fukuhara, MD, Tatsuya Suzuki, MD PhD, Wataru Munakata, MD, Yukio Kobayashi, Kinuko Tajima, Jun Itami, MD PhD, Hirokazu Taniguchi, MD PhD, Kensei Tobinai

Blood (2014) 124 (21): 1761.

https://doi.org/10.1182/blood.V124.21.1761.1761

Published: 2014

Journal Articles

Influence of the Watch and Wait Strategy on the Clinical Outcome in Patients with Follicular Lymphoma in the Rituximab Era

Sayako Yuda, MD, Dai Maruyama, MD PhD, Akiko Miyagi Maeshima, MD PhD, Shin-ichi Makita, MD, Hideaki Kitahara, MD, Miyamoto Ken-ichi, MD, Suguru Fukuhara, MD, Wataru Munakata, MD, Tatsuya Suzuki, MD PhD, Yukio Kobayashi, MD PhD, Kinuko Tajima, Hirokazu Taniguchi, MD PhD, Kensei Tobinai

Blood (2014) 124 (21): 4475.

https://doi.org/10.1182/blood.V124.21.4475.4475

Published: 2014

Journal Articles

Clinicopathological Prognostic Indicators Of 24 Patients With B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma

Ken-ichi Miyamoto, MD, Akiko Miyagi Maeshima, MD, PhD, Hirokazu Taniguchi, MD, PhD, Junko Nomoto, PhD, Hideaki Kitahara, MD, Suguru Fukuhara, MD, Wataru Munakata, MD, Dai Maruyama, MD, PhD, Sung-Won Kim, MD, PhD, Yukio Kobayashi, MD, PhD, Kensei Tobinai, MD, PhD

Blood (2013) 122 (21): 5085.

https://doi.org/10.1182/blood.V122.21.5085.5085

Published: 2013

Journal Articles

High-Dose Cyclophosphamide + G-CSF Mobilization Regimen Have Higher Anti-Myeloma Effects Than G-CSF Alone Regimen – Single Institutional Study in 147 Myeloma Patients From Japan

Akira Tanimura, MD, Masataka Takeshita, MD, PhD, Atsushi Sato, MD, Junichiro Takano, MD, Hideaki Kitahara, MD, Ayato Tsukamoto, MD, Yuko Kimura, MD, Risen Hirai, MD, Miki Nakamura, MD, PhD, Shotaro Hagiwara, MD, PhD, Mineo Kurokawa, MD, PhD, Akiyoshi Miwa, MD

Blood (2011) 118 (21): 2007.

https://doi.org/10.1182/blood.V118.21.2007.2007

Published: 2011

NARROW

The Response Evaluation Criteria in Solid Tumors Can be Substituted for the International Workshop Criteria?: Comparison Using Japan Clinical Oncology Group Study JCOG0203 for Untreated Indolent B-Cell Lymphoma

Prolonged Lymphocytepenia after Bendamustine with or without Rituximab Treatment in Patients with Relapsed or Refractory Indolent B-Cell and Mantle Cell Lymphoma

The Impact of Concurrent Expression of MYC and BCL2 on Outcomes of Localized Primary Gastric Diffuse Large B-Cell Lymphoma Undergoing Rituximab-Containing Chemotherapy with or without Radiotherapy

Influence of the Watch and Wait Strategy on the Clinical Outcome in Patients with Follicular Lymphoma in the Rituximab Era

Clinicopathological Prognostic Indicators Of 24 Patients With B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma

High-Dose Cyclophosphamide + G-CSF Mobilization Regimen Have Higher Anti-Myeloma Effects Than G-CSF Alone Regimen – Single Institutional Study in 147 Myeloma Patients From Japan

Email alerts

ASH Publications

American Society of Hematology

The Response Evaluation Criteria in Solid Tumors Can be Substituted for the International Workshop Criteria?: Comparison Using Japan Clinical Oncology Group Study JCOG0203 for Untreated Indolent B-Cell Lymphoma

Prolonged Lymphocytepenia after Bendamustine with or without Rituximab Treatment in Patients with Relapsed or Refractory Indolent B-Cell and Mantle Cell Lymphoma

The Impact of Concurrent Expression of MYC and BCL2 on Outcomes of Localized Primary Gastric Diffuse Large B-Cell Lymphoma Undergoing Rituximab-Containing Chemotherapy with or without Radiotherapy

Influence of the Watch and Wait Strategy on the Clinical Outcome in Patients with Follicular Lymphoma in the Rituximab Era

Clinicopathological Prognostic Indicators Of 24 Patients With B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma

High-Dose Cyclophosphamide + G-CSF Mobilization Regimen Have Higher Anti-Myeloma Effects Than G-CSF Alone Regimen – Single Institutional Study in 147 Myeloma Patients From Japan

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only